YahooAugust 30, 2026 at 10:00 PM NY4 days ago
Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore
Columvi® (glofitamab) will be added to the Singapore Ministry of Health's (MOH) CDL and MAF List. Starting 1 September 2026, this milestone ensures that eligible Singaporeans and Permanent Residents will have subsidised access to the medication in public healthcare institutions.[1]
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo
Companies in This Story
Related Stories
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill1 hour ago
Discover which S&P500 stocks are making waves on Friday.
ChartMill2 hours ago
Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo3 hours ago
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo3 hours ago
Anthropic's IPO Push Just Got a $15 Billion Backstop
Yahoo3 hours ago